Analysts Offer Insights on Healthcare Companies: Rhythm Pharmaceuticals (RYTM) and Surgery Partners (SGRY)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Rhythm Pharmaceuticals (RYTM – Research Report) and Surgery Partners (SGRY – Research Report) with bullish sentiments.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Rhythm Pharmaceuticals (RYTM)
In a report released today, Dennis Ding from Jefferies maintained a Buy rating on Rhythm Pharmaceuticals, with a price target of $125.00. The company’s shares closed last Thursday at $90.56.
According to TipRanks.com, Ding is a 4-star analyst with an average return of
Rhythm Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $140.29, a 56.3% upside from current levels. In a report issued on February 18, RBC Capital also initiated coverage with a Buy rating on the stock with a $145.00 price target.
See the top stocks recommended by analysts >>
Surgery Partners (SGRY)
In a report released today, Brian Tanquilut from Jefferies maintained a Buy rating on Surgery Partners, with a price target of $16.25. The company’s shares closed last Thursday at $13.95.
According to TipRanks.com, Tanquilut is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Surgery Partners with a $20.31 average price target, which is a 46.3% upside from current levels. In a report issued on March 2, Cantor Fitzgerald also maintained a Buy rating on the stock with a $33.00 price target.
